Corbus Pharmaceuticals stock analysis
Corbus Pharmaceuticals (3371) Stock Price & Analysis
3371 Stock Chart & Stats
- Day’s Range
- EUR 2.75 - EUR 2.75
- 52-Week Range
- EUR 2.23 - EUR 11.26
- Previous Close
- EUR 3.30
- Volume
- N/A
- Average Volume (3M)
- 17
- Market Cap
- EUR 56.54M
- Enterprise Value
- EUR 30.69M
- Total Cash (Recent Filing)
- EUR 115.34M
- Total Debt (Recent Filing)
- EUR 3.91M
- Price to Earnings (P/E)
- ―
- Beta
- 0.95
- Next Earnings
- Mar 15, 2027 (Est.)
- EPS Estimate
- -1.24
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Positive Obesity-program Efficacy And Tolerability
CRB-913 is producing clinically meaningful weight loss across tested doses while maintaining a reported tolerability profile, supporting continued development of Corbus’s oral, non-incretin obesity approach. These results could broaden the pipeline’s strategic value if replicated in later-stage studies.
Progress Toward Pivotal Oncology Development
Advancing TEMPO-1 into Phase 3 represents a meaningful transition from earlier clinical work toward a potentially registrational oncology program. The study’s defined efficacy endpoints and FDA-cleared design provide a clearer development pathway and could improve the pipeline’s maturity over the next several quarters.
Low Financial Leverage
Very low debt reduces interest and repayment pressure relative to a more leveraged biotechnology company, preserving flexibility for research and clinical spending. Although the capital base has declined, limited borrowing obligations remain a structural balance-sheet advantage while Corbus advances its pipeline.
Bears Say
Pre-revenue Model With Widening Losses
Corbus has not yet established product revenue, while losses have expanded sharply as development spending continues. This combination leaves operating performance dependent on successful clinical progress and eventual commercialization, increasing the financial consequences of delays or unsuccessful programs.
Persistent And Worsening Cash Burn
Large negative operating and free cash flow means Corbus is consuming capital rather than funding development internally. Continued outflows can require additional financing and may constrain investment choices, while the link between free cash flow and net loss indicates the losses are translating into real cash usage.
Pipeline Remains Dependent On Clinical Execution
The company’s value remains tied to drug candidates that are still in clinical development rather than established commercial products. Progression through trials, regulatory review, and eventual approval is therefore essential, leaving future operating improvement dependent on execution across multiple development stages.
Corbus Pharmaceuticals News
Corbus’s CRB-913 Obesity Trial Reaches Key Phase 1b Milestone, Putting CRBP on Investors’ Radar
Corbus Pharmaceuticals Holdings ($CRBP) announced an update on their ongoing clinical study. Corbus Pharmaceuticals Inc. is advancing its obesity program with a completed Phase 1b study called “A 2-part, Phase
3371 FAQ
What was Corbus Pharmaceuticals’s price range in the past 12 months?
What is Corbus Pharmaceuticals’s market cap?
When is Corbus Pharmaceuticals’s upcoming earnings report date?
How were Corbus Pharmaceuticals’s earnings last quarter?
Is Corbus Pharmaceuticals overvalued?
Does Corbus Pharmaceuticals pay dividends?
What is Corbus Pharmaceuticals’s EPS estimate?
How many shares outstanding does Corbus Pharmaceuticals have?
What happened to Corbus Pharmaceuticals’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Corbus Pharmaceuticals?
What is the TipRanks Smart Score and how is it calculated?
Corbus Pharmaceuticals Stock Smart Score
Company Description
Corbus Pharmaceuticals
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Yuval Cohen
- Employees
- 36
- Website
- www.corbuspharma.com
- Address
- 500 River Ridge Drive, Norwood, MA, 02062, US
Corbus Pharmaceuticals (3371) Earnings & Revenues
3371 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 1 | 6 | 15 |
| Technical Analysis | 1 | 6 | 3 |
| Moving Averages | 0 | 0 | 12 |











